Lin BioScience Past Earnings Performance
Past criteria checks 0/6
Lin BioScience's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 19.2% annually.
Key information
-27.1%
Earnings growth rate
-21.6%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | n/a |
| Return on equity | -27.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Lin BioScience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -732 | 258 | 1,018 |
| 31 Mar 24 | 0 | -709 | 251 | 936 |
| 31 Dec 23 | 0 | -687 | 243 | 854 |
| 30 Sep 23 | 0 | -603 | 213 | 728 |
| 30 Jun 23 | 0 | -518 | 183 | 601 |
| 31 Mar 23 | 0 | -416 | 153 | 461 |
| 31 Dec 22 | 0 | -314 | 124 | 321 |
| 30 Sep 22 | 0 | -252 | 109 | 269 |
| 30 Jun 22 | 0 | -190 | 94 | 217 |
| 31 Mar 22 | 0 | -380 | 97 | 235 |
| 31 Dec 21 | 0 | -435 | 94 | 245 |
| 30 Sep 21 | 0 | -415 | 78 | 222 |
| 30 Jun 21 | 0 | -394 | 62 | 200 |
| 31 Mar 21 | 0 | -186 | 53 | 156 |
| 31 Dec 20 | 0 | -152 | 52 | 145 |
| 30 Sep 20 | 0 | -197 | 47 | 161 |
| 30 Jun 20 | 0 | -243 | 42 | 178 |
| 31 Mar 20 | 0 | -259 | 45 | 199 |
| 31 Dec 19 | 0 | -235 | 45 | 193 |
| 30 Sep 19 | 0 | -209 | 48 | 167 |
| 30 Jun 19 | 0 | -183 | 51 | 141 |
| 31 Mar 19 | 0 | -161 | 51 | 123 |
| 31 Dec 18 | 0 | -139 | 52 | 104 |
| 30 Sep 18 | 0 | -134 | 49 | 100 |
| 30 Jun 18 | 0 | -128 | 46 | 97 |
| 31 Mar 18 | 0 | -144 | 42 | 110 |
| 31 Dec 17 | 0 | -159 | 38 | 123 |
| 31 Dec 16 | 0 | -63 | 14 | 49 |
Quality Earnings: 6696 is currently unprofitable.
Growing Profit Margin: 6696 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6696 is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare 6696's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6696 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (33.2%).
Return on Equity
High ROE: 6696 has a negative Return on Equity (-27.45%), as it is currently unprofitable.